MCI, SCD
Conditions
Keywords
keton, MCI, SCD, CBF, DMN
Brief summary
The primary objectives of this pilot study are to test if a single dose of an oral ketone monoester supplement will increase blood flow and connectivity in the brain in adults with subjective cognitive decline (SCD) or mild cognitive impairment (MCI). The main questions it aims to answer are: Does a single dose of an oral ketone supplement increase global cerebral blood flow (CBF)? Does a single dose of an oral ketone supplement improve resting-state functional connectivity in the Default Mode Network (DMN)? Does the increase in CBF positively correlate with improved functional connectivity in the DMN? Participants will: * Attend one 2-hour session, which includes: * Neurocognitive assessment * MRI Scans (two, each 15 Minutes) * Capillary blood ketone level measurements * Hemodynamic assessment (blood pressure, heart rate)
Detailed description
In this non-randomized, single-arm study participants will undergo a baseline MRI scan to assess functional connectivity in the DMN and resting CBF without ketone supplementation. Participants will then consume 0.3 g/kg body weight of a ketone monoester supplement (∆G Tactical) and then rest for 70 minutes. Participants will then undergo a second MRI scan to evaluate changes in functional connectivity and CBF, with capillary β-OHB and blood pressure measured before and after each scan. The entire experimental visit, including scans and assessments, will last up to 2 hours.
Interventions
DIETARY_SUPPLEMENTOral ketone monoester (KME)
The oral ketone monoester supplement should increase the global CBF and improve resting-state connectivity in the DMN in adults with SCD or MCI. The participants will take one dose of the supplement followed by measurement, to figure out if there are any noticeable changes.
Sponsors
University Department of Geriatric Medicine FELIX PLATTER
McMaster University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adults aged 55 years or older * Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI) SCD CRITERIA: * Self-experienced, persistent decline of cognitive abilities within the last 5 years in relation to a previously normal status * Normal results on demographically adjusted standardized cognitive tests * Accompanied by concerns associated with SCD and a feeling of worse performance than others in the same age group * Decline must not be related to a specific event or explained by a specific disease, medical disorder, medication, or substance abuse MCI CRITERIA * Fulfils criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5): * Demographically adjusted performance between -1 and -2 SD below average in one or more cognitive domains on standardized cognitive tests * Accompanied by concern from the individual, a knowledgeable informant, or clinician indicating mild cognitive decline * Capacity for independent daily activities is maintained
Exclusion criteria
* Clinical diagnoses of psychiatric disorders (e.g., anxiety disorders, depression) * Diagnosed major neurocognitive disorder (i.e., dementia) * Association of SCD or MCI with delirium * Diagnosed cardiometabolic disease (Uncontrolled hypertension (systolic blood pressure \>160 mm Hg, and/or diastolic blood pressure \>100 mm Hg, Type 2 diabetes) * Substance use disorder * History of heart attack or stroke requiring hospitalization in the past 3 years * MRI contraindications, including implanted medical devices * Experiencing residual fatigue, brain fog, or tiredness post-acute illness (i.e., long-COVID) * Severe literacy, visual, hearing, and/or speech impairment that would make participation in the study difficult or impossible * Individuals who are not fluent in Swiss German or German
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Functional connectivity of the DMN | 90 minutes | Functional connectivity of the default mode network (DMN) is measured via functional MRI. Changes in BOLD signal in each region are determined by independent component analysis and then functional connectivity is measured as a Pearson correlation (r) between the neural regions comprising the DMN and transformed into a z score. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cerebral blood flow | 90 minutes | Sum of blood flow in the internal carotid and vertebral arteries via phase contrast MRI in ml/min. |
Countries
Switzerland
Contacts
PRINCIPAL_INVESTIGATORSabine Krumm, PD, PhD
University Department of Geriatric Medicine FELIX PLATTER
Outcome results
None listed